Zynex Inc Stock Price, News & Analysis

Zynex (NASDAQ: ZYXI), a medical technology company focused on non-invasive medical devices for pain management, rehabilitation, and patient monitoring, has scheduled its Q2 2025 earnings conference call for July 31, 2025, at 4:15 PM ET.

The company will release its financial results for the quarter ended June 30, 2025, before the call. Management will host the call followed by a Q&A session. Participants can join via phone using the U.S. & Canada dial-in (800-836-8184) or international number (646-357-8785), or through the webcast available on the company's investor relations website.

Zynex (NASDAQ: ZYXI), a medical technology company focused on non-invasive medical devices, announced that Tricare, their largest insurance customer, will continue its temporary payment suspension. Despite appealing the suspension and meeting with Tricare officials in April to present data supporting the lifting of the suspension, Tricare has decided to maintain the temporary hold while conducting further review.

The company's CEO, Thomas Sandgaard, confirmed that the suspension will remain in effect until Tricare reaches its final decision. This development represents a significant challenge for Zynex, as Tricare is identified as their largest insurance customer.

Zynex (NASDAQ: ZYXI), a medical technology company focused on noninvasive medical devices for pain management, rehabilitation, and patient monitoring, has announced the appointment of Steven Dyson as its new Chief Executive Officer, effective August 18, 2025.

Dyson brings over 25 years of experience in the medical technology sector, primarily through his leadership at Apax, a global private equity firm. His extensive background includes significant board and transaction experience with various healthcare and medtech companies worldwide, including KCI, Rodenstock, Healthium Medtech, Unilabs, and Neuraxpharm.

Thomas Sandgaard, Zynex's Founder and current Chairman, will step back from day-to-day operations but remain actively involved as Chairman and Chair of the Board's Technology Committee. Dyson will operate from the company's headquarters in Englewood, Colorado, while maintaining a residence in London, England.

Zynex (NASDAQ: ZYXI) has secured UK patent 2617515 for a novel multiparameter, noninvasive sepsis monitoring device. The technology aims to address a critical global health crisis, as sepsis affects 1.7 million people annually in the US alone and causes 11 million deaths globally, with one-third of hospital deaths being sepsis-related.

The device will continuously monitor physiological signals to provide early alerts about patient sepsis status, leveraging Zynex's cardiac monitoring expertise. Early detection is crucial for patient recovery, as highlighted by the Surviving Sepsis Campaign. The technology could significantly impact treatment outcomes, particularly considering that over 50% of sepsis cases are hospital-acquired and current detection methods face timing challenges.

Zynex reported challenging Q1 2025 financial results, with net revenue declining to $26.6 million from $46.5 million year-over-year. The medical technology company faced a temporary payment suspension from its largest insurance customer, Tricare, with an appeals response expected in June.

Key financial metrics include:

• Gross profit: $18.2 million (69% of revenue), down from $37.2 million (80%)
• Net loss: ($10.4 million) or ($0.33) per share
• Cash position: $23.9 million with working capital of $40.1 million

The company implemented cost-reduction measures, including a 15% staff reduction, targeting annual savings of $35 million. Despite challenges, Zynex maintains optimism about growth opportunities in pain management and patient monitoring, with plans to submit their NiCO laser pulse oximeter for FDA approval. Q2 2025 guidance projects revenue of at least $27 million with an expected loss per share of ($0.20) or better.

Zynex (NASDAQ: ZYXI), a medical technology company focused on non-invasive medical devices for pain management, rehabilitation, and patient monitoring, has scheduled its first quarter 2025 earnings conference call for Tuesday, April 29, 2025 at 4:15 PM Eastern Time.

The company will release its financial results for Q1 2025 (ended March 31, 2025) prior to the call. Management will host the conference call followed by a Q&A session. Participants can join via U.S. & Canada dial-in (800-836-8184), international number (646-357-8785), or through the webcast link available on the company's investor relations website.

Zynex (NASDAQ: ZYXI) reported its Q4 and full-year 2024 financial results, showing mixed performance. Full-year 2024 highlights include a 4% revenue increase to $192.4 million, net income of $3.0 million (EPS $0.09), and operating cash flow of $12.7 million.

However, Q4 2024 showed challenges with revenue declining to $46.0 million from $47.3 million year-over-year, resulting in a net loss of ($0.6) million. A significant development is Tricare's temporary payment suspension, affecting 20-25% of annual revenue. In response, Zynex is implementing a 15% staff reduction and other cost-cutting measures, expected to save approximately $35 million annually.

The company received FDA clearance for its new TensWave device and completed positive clinical trials for the NiCO laser pulse oximeter at Duke University. For Q1 2025, Zynex projects revenue of at least $30 million with an expected loss per share of ($0.30) or better.

Zynex (NASDAQ: ZYXI), a medical technology company focused on non-invasive medical devices for pain management, rehabilitation, and patient monitoring, has scheduled its Q4 and full-year 2024 earnings conference call for March 11, 2025, at 4:15 PM Eastern Time.

The company will release its financial results before the call, which will include a management presentation followed by a Q&A session. Participants can join via phone using U.S. & Canada dial-in (800-836-8184) or international number (646-357-8785), or through the webcast link available on the company's investor relations website.

Zynex (NASDAQ: ZYXI) has announced a new partnership to conduct business with Veterans Affairs Medical Centers (VAMCs) across the United States. This collaboration gives Zynex access to the VA's extensive healthcare network, which spends over $112 billion annually on healthcare and serves over 9 million enrolled veterans.

The partnership encompasses 171 VAMCs and over 1,100 outpatient facilities, plus approximately 700 Military Treatment Facilities operated by the Department of Defense. Currently, less than 1% of Zynex's sales come from VAMCs, presenting a significant growth opportunity for the company's non-opioid pain management solutions.